UTILITY Therapeutics - Developing Antibiotics to Treat Drug …
WEBUTILITY Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections.
About Us – Utility Therapeutics
WEBOur core mission: Bringing novel mode of action therapies to people in the United States suffering from urinary tract infections. Urinary tract infections (UTIs) are among the most common bacterial infections worldwide. 1 Each year more than 30 million people in the United States are treated for UTIs. 2,3.
Utility Therapeutics wins FDA nod for UTI antibiotic that has …
WEBApr 25, 2024 · The FDA has approved Utility Therapeutics’ Pivya, the first new treatment in the U.S. for uncomplicated urinary tract infections in more than 20 years.
Our Focus – Utility Therapeutics
WEBUTILITY therapeutics has acquired the US rights to 2 European-approved antibiotics offering a new type of treatment with a unique mode of action — novel in the US market — to patients suffering from UTIs.
UTILITY therapeutics Ltd. Announces Financing Led by the AMR …
WEBJan 17, 2024 · UTILITY has exclusive U.S. commercial rights to two European-approved antibiotics, pivmecillinam and mecillinam, for the treatment of urinary tract infections (UTI).
FDA Approves Antibiotic to Treat Urinary Infections - The New York Times
WEBApr 24, 2024 · Utility Therapeutics, the U.S. company that acquired the rights to pivmecillinam, said it would be available in 2025. The company is also seeking F.D.A. approval for an intravenous version of...
UTILITY therapeutics Ltd. Announces Financing Led by the AMR ... - BioSpace
WEBJan 17, 2024 · UTILITY therapeutics Ltd., a biotechnology company focused on the development and commercialization of two European-approved antibiotics for the treatment of urinary tract infections in the U.S., announced a private …
FDA Approves UTILITY’s New Antibiotic for Uncomplicated
WEBApr 25, 2024 · The FDA on Wednesday approved the use of UTILITY therapeutics’ oral antibiotic pivmecillinam, which will now carry the brand name Pivya, for the treatment of adult women with uncomplicated urinary tract infections.
UTILITY Therapeutics Announces Capital Raise and 2021 …
WEBFeb 4, 2021 · UTILITY has exclusive U.S. commercial rights to two European-approved antibiotics, pivmecillinam and mecillinam, for the treatment of urinary tract infections (UTI).
UTILITY therapeutics - LinkedIn
WEBUTILITY therapeutics Ltd., a biotechnology company focused on the U.S. development and commercialization of two European-approved antibiotics for the treatment of urinary tract infections (UTI,...
Skip to content